Fig. 1.

Effect of alirocumab, atorvastatin, and their combination on average plasma TC (A) and TG (B) levels as measured throughout the 18-week study. Lipoprotein profiles for cholesterol were assessed by FPLC lipoprotein separation to study effects of alirocumab alone (C) and in combination with atorvastatin (D). * P < 0.05, *** P < 0.001 as compared with control; ††† P < 0.001 as compared with atorvastatin; ‡ P < 0.05, ‡‡ P < 0.01, ‡‡‡ P < 0.001 for 3 mg/kg alirocumab compared with 10 mg/kg alirocumab (n = 15 per group).